Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
Schedule
Product: Fasturtec
Active Ingredient: Rasburicase 1.5mg
Dosage Form: Powder for infusion
New Zealand Sponsor: sanofi-aventis new zealand limited
Manufacturers: Glaxo Wellcome Production, Notre Dame de Bondeville, France
Gruppo Lepetit SRL, Anagni, Italy
Note: This renewed consent is valid for two years from 1 August 2010.
Dated this 10th day of June 2010.
STEWART JESSAMINE, Acting Deputy Director-General, Regulation and Governance Directorate, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).